Safeguarding public health CHMP's view on multiplicity; through assessment, advice and guidelines

Similar documents
Safeguarding public health Subgroup analyses scene setting from the EU regulators perspective

Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable

EMA Workshop on Multiplicity Issues in Clinical Trials 16 November 2012, EMA, London, UK

The update of the multiplicity guideline

Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases Draft

Reflection paper on assessment of cardiovascular safety profile of medicinal products

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

Reflection paper on the use of extrapolation in the development of medicines for paediatrics

Introduction to Clinical Trials - Day 1 Session 2 - Screening Studies

Guideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

Ref: E 007. PGEU Response. Consultation on measures for improving the recognition of medical prescriptions issued in another Member State

Annex. Scientific conclusions and grounds for refusal presented by the European Medicines Agency

Practical Statistical Reasoning in Clinical Trials

Missing data in clinical trials: a data interpretation problem with statistical solutions?

confirmatory clinical trials - The PMDA Perspective -

How to weigh the strength of prior information and clarify the expected level of evidence?

How to use prior knowledge and still give new data a chance?

Further data analysis topics

Effective Implementation of Bayesian Adaptive Randomization in Early Phase Clinical Development. Pantelis Vlachos.

Biostatistics Primer

(Regulatory) views on Biomarker defined Subgroups

BACKGROUND + GENERAL COMMENTS

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016

E11(R1) Addendum to E11: Clinical Investigation of Medicinal Products in the Pediatric Population Step4

Secretary-General of the European Commission, signed by Mr Jordi AYET PUIGARNAU, Director

Treatment changes in cancer clinical trials: design and analysis

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Design for Targeted Therapies: Statistical Considerations

ICH Topic E 5 (R1) Questions and Answers Ethnic Factors in the Acceptability of Foreign Clinical Data. Step 5 QUESTIONS AND ANSWERS (CPMP/ICH/289/95)

Background EVM. FAO/WHO technical workshop on nutrient risk assessment, Geneva, May 2005, published 2006.

Evidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co.

Lecture 2. Key Concepts in Clinical Research

Chapter 19. Confidence Intervals for Proportions. Copyright 2010, 2007, 2004 Pearson Education, Inc.

Discussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK

ICH E9 (R1) Addendum on Estimands and Sensitivity Analysis

Specific Challenges for Orphan Drugs with Paediatric Development

ICH E9(R1) Technical Document. Estimands and Sensitivity Analysis in Clinical Trials STEP I TECHNICAL DOCUMENT TABLE OF CONTENTS

Transmission to CHMP July Adoption by CHMP for release for consultation 20 July Start of consultation 31 August 2017

PGEU GPUE. Pharmaceutical Group of European Union Groupement Pharmaceutique de l Union Européenne

Chapter 19. Confidence Intervals for Proportions. Copyright 2010 Pearson Education, Inc.

Disclaimer. Statistical Aspects of Revision of CHMP Bioequivalence Guidelines. David Brown MHRA

Power & Sample Size. Dr. Andrea Benedetti

Quality Digest Daily, March 3, 2014 Manuscript 266. Statistics and SPC. Two things sharing a common name can still be different. Donald J.

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA

P values From Statistical Design to Analyses to Publication in the Age of Multiplicity

CV safety in COPD? Impact of Guidances and Whitepaper Regulatory position in Europe?

MHRA Pharmacovigilance System Master File (PSMF) Inspection Findings

ANONYMOUS, NON CONTACTABLE v ASTRAZENECA

Improving new drug development for paediatric cancer: the EMA and PDCO vision

Improving Adverse Drug Reaction Information in Product Labels. EFSPI IDA Webinar 28 th Sept 2017 Sally Lettis

EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL. PHARMACEUTICAL COMMITTEE 21 October 2015

Clinical Trials. Susan G. Fisher, Ph.D. Dept. of Clinical Sciences

Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia

Workshop report: Participants not subjects engaging patients and families in paediatric clinical research

Biostatistics 3. Developed by Pfizer. March 2018

WORK PLAN FOR THE EFFICACY WORKING PARTY (EWP) CHAIRPERSON: Barbara van Zwieten-Boot

Estimands. EFPIA webinar Rob Hemmings, Frank Bretz October 2017

On the Utility of Subgroup Analyses in Confirmatory Clinical Trials

Summary of product characteristics (SmPC)

Should Cochrane apply error-adjustment methods when conducting repeated meta-analyses?

A GUIDELINE ON CHANGING THE CLASSIFICATION FOR THE SUPPLY OF A MEDICINAL PRODUCT FOR HUMAN USE

How to design a pilot study

The Roles of Short Term Endpoints in. Clinical Trial Planning and Design

Swiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab)

Improvising Claims. - Dr. R. B. Smarta

Discussion of Changes in the Draft Preamble

Overview of requirements for surrogate endpoint adoption by CHMP: a regulatory perspective. Dr Beatriz Flores CDDF- October 2017

Population Enrichment Designs Case Study of a Large Multinational Trial

What role should formal riskbenefit decision-making play in the regulation of medicines?

Cost-effectiveness of cladribine (Mavenclad ) for the

Exploring uncertainty in cost effectiveness analysis. Francis Ruiz NICE International (acknowledgements to: Benjarin Santatiwongchai of HITAP)

Estimands and Sensitivity Analysis in Clinical Trials E9(R1)

Concept paper on a Guideline for allergen products development in moderate to low-sized study populations

Good Practice Notes on School Admission Appeals

Concept paper on the guidance on the non-clinical and clinical development of medicinal products for HIV prevention including oral and topical PrEP

Quality, Safety and Sourcing in Unlicensed Medicines

Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarkers detection and subgroup identification

The European Medicines Agency (EMA)

The Sildenafil Controversy

Technology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476

Drug Development in Paediatric Oncology

Quantitative challenges of extrapolation

Selection and estimation in exploratory subgroup analyses a proposal

The Clean Environment Commission. Public Participation in the Environmental Review Process

ADDING VALUE AND EXPERTISE FOR SUCCESSFUL MARKET ACCESS. Per Sørensen, Lundbeck A/S

EMEA experience with endpoints for Oncology drug approval

Welcome to this third module in a three-part series focused on epidemiologic measures of association and impact.

Pharmacometric Modelling to Support Extrapolation in Regulatory Submissions

The Paediatric Committee (PDCO)

EMEA WORKING PARTY ON HERBAL MEDICINAL PRODUCTS

STA Learning Objectives. What is Population Proportion? Module 7 Confidence Intervals for Proportions

STA Module 7 Confidence Intervals for Proportions

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care

Helmut Schütz. BioBriges 2018 Prague, September

NASH Regulatory Landscape. Veronica Miller, PhD Forum for Collaborative Research UC Berkeley SPH

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON EVALUATION OF ANTICANCER MEDICINAL PRODUCTS IN MAN

9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. Health systems and products Medicinal products authorisations, EMA

Transcription:

Safeguarding public health CHMP's view on multiplicity; through assessment, advice and guidelines Rob Hemmings Statistics Unit Manager, MHRA CHMP member Chair, CHMP Scientific Advice Working Party Biostatistics Working Party Member

Disclaimer If the CHMP chair disagrees he will say so Slide 2

Contents Multiplicity issues in clinical trials Relevant guidelines General comments and literature reference Special topics Assessment Scientific Advice Conclusions Slide 3

What are multiplicity issues in clinical trials? More than one chance to win - to win what? - A marketing authorisation (MA)? - A trial that is formally a success? - Statement on an individual endpoint? Multiplicity of inferences is present in virtually all clinical trials. understatement? all benefit-risk decisions are holistic. Multiple testing is necessary; some is confirmatory, some is exploratory. The usual concern with multiplicity is that, if it is not properly handled, unsubstantiated claims for the effectiveness of a drug may be made as a consequence of an inflated rate of false positive conclusions. Proper interpretation of MA, trial, endpoint all requires awareness of this multiplicity concept so that strength of evidence is properly understood. Slide 4

Guidelines E9 Multiplicity may arise from multiple primary variables, multiple comparisons of treatments, repeated evaluation over time and/or interim analyses. = Problem statement Methods to avoid or reduce multiplicity are sometimes preferable when available, such as the identification of the key primary variable (multiple variables), the choice of a critical treatment contrast (multiple comparisons) In confirmatory analyses, any aspects of multiplicity which remain after steps of this kind have been taken should be identified in the protocol; adjustment should always be considered = Solutions, pre-specification and adjustment Slide 5

Guidelines Multiplicity issues in clinical trials A clinical study that requires no adjustment of the type I error is one that consists of the two treatment groups, that uses a single primary variable, and has a confirmatory statistical strategy that pre-specifies just one single nullhypothesis relating to the primary variable and no interim analysis all other situations require attention to the potential effects of multiplicity. The guideline describes matters for which multiplicity should be considered: endpoints, doses, timepoints, hypotheses, subgroups. Focus is at the level of the trial. Other topics: secondary endpoints, subgroups, responder analyses, composite endpoints Slide 7

Guidelines SmPC Clinical Efficacy and Safety - It may be appropriate to provide limited information, relevant to the prescriber, such as the main results (statistically compelling and clinically relevant) regarding pre-specified end points or clinical outcomes in the major trials Such information on clinical trials should be concise, clear, relevant and balanced Paediatric population - the main results regarding pre-specified endpoints should be provided, whether positive or negative. If data are considered inconclusive, this should be stated. Slide 8

General comments Regulatory philosophy - Ensure evidence of therapeutic efficacy - Ensure positive risk-benefit - Product information that is instructive and informative - Licensing decisions that are proportionate and scientific without compromising standards Since licensing (risk-benefit) decisions are holistic, statistical methods to handle of multiplicity are, formally, neither necessary nor sufficient but: - makes for a more simple life - facilitates planning for the sponsor and a more predictable regulatory review - enhances (statistical) strength of evidence Slide 9

General comments Multiplicity is generally well-handled through prespecification, hierarchy and adjustment Until things go wrong and the potential for Texas sharpshooting explains the emphasis on pre-specification and Type I error control This is not a controversial guideline, why think about changing it? - New strategies - Multi-regional drug development - Subgroups for confirmatory conclusions - Evidence at interim (or anytime nominal level adjusted?) - Simultaneous confidence intervals Slide 10

Literature reference Dr Ian Malcolm (Jeff Goldblum) your scientists were so preoccupied with whether they could that they didn't stop to think if they should. Important questions: 1. Must we address multiplicity? OR 2. Is it preferable to address multiplicity? AND ONLY THEN 3. How to address multiplicity? Licensing Decision Stat method Slide 11

Special topics new strategies 1. Using alpha - Brilliant - All advances welcome where must or preferable 2. Demonstrating control of alpha - Simulation Slide 12

Special topics secondary endpoints Secondary endpoints - Usually: variables expressing supportive evidence no claims are intended tests are exploratory - Sometimes: variables which may become the basis for additional claims For discussion (though not here!) - Pulmonary Hypertension and Erectile Dysfunction - Treatment and Maintenance of effect - Disability progression in RRMS or Structural Damage in RA - SGRQ / TDI in asthma - ORR in last line oncological indication Slide 13

Special topics secondary endpoints SmPC section 4.1 vs 5.1 helps Decision-making is not only statistical - Totality of data - Pharmacology / biological plausibility / External evidence Scenario 1 - New pharmacological class, uncertain mechanism, single pivotal trial Scenario 2 - Known pharmacological class, clear mechanism, multiple pivotal trials Increases (statistical) strength of evidence Should consideration of need to adjust and how to adjust go beyond the data from the trial? Communication between disciplines to be improved? Are hierarchies non-sensical? Slide 14

Special topics interim decisions Trial stops for efficacy at p=0.001 based on primary endpoint - Should consider more but that s another talk How to quantify effects - 95% CIs - 99.9% CIs What about secondary variables? More complex for stopping at 2 nd, 3 rd interim analysis? Slide 15

Special topics multi-regional development 1. Investigating regional differences - Discussed elsewhere under subgroups 2. Addressing different requirements / preferences between regions - Conduct separate development programmes, or plan a programme with several pivotal trials which individually prioritise the standards for different regions. - Increase the size of the trial so that it can simultaneously achieve all regulatory requirements within one framework without loss of power - Choose one set of regulatory standards over others for the purpose of planning and reporting; possibly, the highest hurdle - Develop multiple SAPs for a single trial, so that the same trial data separately analysed will address the different standards of each region. Slide 16

Special topics multi-regional development Multiple SAPs = multiple chances to win. Not in EU still one chance to win Not without problems Slide 17

Assessment Strict on confirmatory, scientific on exploratory Secondary endpoints treated as supportive Lower standards? - No, balance of data, science, pharmacology, communication - Nominal significance levels are important for planning and analysing RCTs - Matters important for prescribers are not only those with statistical significance proven to the highest standards - Need to be better at describing uncertainty? Marketing authorisation, meta-analyses, safety data Multiple SAPs have been accepted Slide 18

Scientific Advice Multiplicity is generally well-handled through prespecification, hierarchy and adjustment Multiple SAPs - Accepted if the best solution Complex adjustments - Is our complex adjustment acceptable? Yes. - Is our adjustment necessary good question! Slide 19

Concluding remarks Proper interpretation of MA, trial, endpoint all requires awareness of this multiplicity concept but this is not a statistical problem it is instead a problem for inference, and hence design, that can be addressed through statistical methods. Solutions must respect context. Plenty of room for further discussion, e.g. - Type I error control validated by simulation - What constitutes an additional claim? New methods to be understood and integrated, but don t be so preoccupied with whether you could that you don t stop to think about whether you should. Slide 20